Skip to main content
Clinical Trials/NCT03973164
NCT03973164
Completed
Not Applicable

Bone Marrow Cytology, Pathology and 18F-FDG PET/CT and Pelvic MRI in the Diagnosis of Lymphoma Bone Marrow Invasion

Guangxi Medical University1 site in 1 country142 target enrollmentFebruary 2, 2018
ConditionsLymphoma

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Lymphoma
Sponsor
Guangxi Medical University
Enrollment
142
Locations
1
Primary Endpoint
Agreement Between MRI and Bone marrow cytology, pathology and follow-up at Diagnosis
Status
Completed
Last Updated
6 years ago

Overview

Brief Summary

The diagnosis of lymphoma bone marrow infiltration is very important for the staging and treatment mode of lymphoma. Traditional bone marrow cytology and pathology examinations are only performed locally, and missed diagnosis is possible. The study explore the value of multi-parameter pelvic magnetic resonance in detecting bone marrow infiltration with newly diagnosed lymphoma patients . This study also explore the consistency of pelvic magnetic resonance and PET/CT for detection of lymphoma bone marrow infiltration.

Registry
clinicaltrials.gov
Start Date
February 2, 2018
End Date
May 22, 2019
Last Updated
6 years ago
Study Type
Observational
Sex
All

Investigators

Sponsor
Guangxi Medical University
Responsible Party
Principal Investigator
Principal Investigator

Chengcheng Liao

Principal Investigator

Guangxi Medical University

Eligibility Criteria

Inclusion Criteria

  • Lymphoma subtypes were diagnosed on the basis of tissue samples obtained by biopsy or surgery according to the criteria outlined in the current World Health Organization (WHO) classification of hematologic and lymphoid malignancies, by are reference pathologist.
  • Patients who gave written informed consent were referred for MRI.
  • Stable physical medical conditions (patients conscious and comfortable, scheduled for an elective diagnostic imaging).

Exclusion Criteria

  • Pregnancy, general contraindications to MRI.

Outcomes

Primary Outcomes

Agreement Between MRI and Bone marrow cytology, pathology and follow-up at Diagnosis

Time Frame: Within 30 days prior to start of chemotherapy

MRI-positive lesions that cannot be confirmed by bone marrow cytology and pathology will be confirmed by MRI follow-up.

Secondary Outcomes

  • Agreement Between MRI and 18F-FDG PET/CT at Diagnosis(Within 30 days prior to start of chemotherapy)

Study Sites (1)

Loading locations...

Similar Trials